Identification of favorable subgroups for alternative anti-androgen therapy in castration-resistant prostate cancer.
In conclusion, a longer duration of initial MAB and the absence of severe bone metastasis may predict a favorable response to alternative anti-androgen therapies in CRPC patients. Alternative anti-androgen therapy may still be beneficial for these patients, but this needs to be investigated further.
PMID: 31620284 [PubMed]
Source: Clinical Prostate Cancer - Category: Cancer & Oncology Authors: Suzuki K, Terakawa T, Shigemura K, Furukawa J, Harada K, Hinata N, Nakano Y, Fujisawa M Tags: Mol Clin Oncol Source Type: research